Aclarubicin
As of the edition of 20 October 2026, Aclarubicin is a small molecule: in active development; acts on TOP1, TOP2A and TOP2B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2019
- Kind
- Small molecule
- Registered trials
- 16, 0 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 0 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 6 | 1 | 3 | 0 |
| Phase 3 | 6 | 0 | 4 | 0 |
| All trials | 16 |